Results for: CING

Cingulate Inc. (CING) shares are experiencing a surge on Friday, driven by the company’s announcement of a Precision Timed Release (PTR) technology designed to enhance ADHD drug delivery. The technology aims to improve the onset and efficacy of existing ADHD treatments, attracting investor interest. Zacks Small-Cap Research has also issued a positive note, valuing CING at $70. This article details CING’s price action, key metrics, and provides a guide on how to buy the stock.

Cingulate Inc.’s (CING) shares skyrocketed after the company secured a European patent for its groundbreaking ADHD treatment, CTx-1301. This patent covers a significant portion of Europe, including the UK, solidifying Cingulate’s position in the global ADHD market. The company is also preparing to submit a New Drug Application (NDA) to the FDA, marking a crucial step towards bringing this innovative treatment to US patients.